Monte Rosa Therapeutics, Inc.
GLUE
Amendment
Ownership
5.10%
Total Shares
3,334,669
Issuer CIK
1826457
CUSIP
61225M102
Event Date
Nov 9, 2025
Accepted
Nov 12, 2025, 04:13 PM
SEC EDGARView Original Filing
Reporting Persons (6)
Joint Filing
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Versant Venture Capital VI, L.P. | Partnership | 5.10% | 3,334,669 | 3,334,669 | 0 |
| Versant Ventures VI GP, L.P. | Partnership | 5.10% | 3,334,669 | 0 | 3,334,669 |
| Versant Ventures VI GP-GP, LLC | Other | 5.10% | 3,334,669 | 0 | 3,334,669 |
| Versant Vantage I, L.P. | Partnership | 2.40% | 1,573,453 | 1,573,453 | 0 |
| Versant Vantage I GP, L.P. | Partnership | 2.40% | 1,573,453 | 0 | 1,573,453 |
| Versant Vantage I GP-GP, LLC | Other | 2.40% | 1,573,453 | 0 | 1,573,453 |
Disclosure Items (2)
Security Title
Common Stock, par value $0.0001 per share
Issuer Name
Monte Rosa Therapeutics, Inc.
Issuer Address
321 Harrison Avenue, Boston, MA, 02118
Percentage of Class
See Items 7-11 and 13 of the cover pages of this Amendment for each Reporting Person and the corresponding comments.
Number of Shares
See Items 7-11 and 13 of the cover pages of this Amendment for each Reporting Person and the corresponding comments.
Transactions
On November 10, 2025, Versant VI effected a pro rata distribution without additional consideration of 744,800 shares of Common Stock to its limited partners.